What is Bangkok Genomics Innovation PCL Net Margin %?
Bangkok Genomics Innovation PCLBKK:BKGI -2.88%45 Net Margin % is 18.28% as of Dec. 2025, which is 31% above its 10-year median of 13.98. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 82.76% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's Net Margin % or its related term are showing as below:
BKK:BKGI'
s Net Margin % Range Over the Past 10 Years
Min: 10.32 Med: 13.98 Max: 27.86
Current: 11.95
BKK:BKGI's Net Margin % is ranked better than 82.76% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs BKK:BKGI: 11.95
Bangkok Genomics Innovation PCL (BKK:BKGI) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bangkok Genomics Innovation PCL Net Margin % Related Terms
Bangkok Genomics Innovation PCL Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL Net Margin % Chart
BKK:BKGI vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Net Margin % of 18.28% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 31% above median its historical median of 13.98. Over the past decade, Bangkok Genomics Innovation PCL's Net Margin % has ranged from 10.32 to 27.86. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #35 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 17.2%.
Is Bangkok Genomics Innovation PCL's Net Margin % too high?
Bangkok Genomics Innovation PCL's current Net Margin % of 18.28% is 31% above median its 10-year median of 13.98. Over the past 10 years, this metric has ranged from a low of 10.32 to a high of 27.86. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #35 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #35 out of 203 companies for Net Margin %. This places Bangkok Genomics Innovation PCL in the top 17% of its industry — outperforming the majority of peers. Historically, Bangkok Genomics Innovation PCL's own Net Margin % has ranged from 10.32 to 27.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Net Margin % is 18.28%, which is 31% above median its own 10-year median of 13.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Net Margin % of 18.28%. The current Net Margin % is 18.28%, which is 31% above median its 10-year median of 13.98. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Net Margin % is 18.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
